TY  - JOUR 
AU  - Hijazi Vega, Maruan
AU  - Casado, Pedro
AU  - Akhtar, Nosheen
AU  - Alvarez-Teijeiro, Saul
AU  - Rajeeve, Vinothini
AU  - Cutillas, Pedro R
PY  - 2022
SN  - 1535-9476
UR  - http://hdl.handle.net/10366/154968
AB  - PI3K-mammalian target of rapamycin and MAPK/ERK kinase (MEK)/mitogen-activated protein kinase (MAPK) are the most frequently dysregulated signaling pathways in cancer. A problem that limits the success of therapies that target individual PI3K-MAPK...
LA  - eng
KW  - phosphoproteomics
KW  - kinase activity
KW  - eEF2K
KW  - cancer
KW  - AML
KW  - biomarkers
KW  - synergy
KW  - combination therapy
KW  - Biomarkers, Pharmacological
KW  - 14-3-3 Proteins
KW  - Cell Line, Tumor
TI  - eEF2K Activity Determines Synergy to Cotreatment of Cancer Cells With PI3K and MEK Inhibitors
DO  - 10.1016/j.mcpro.2022.100240
T2  - Molecular & Cellular Proteomics
VL  - 21
M2  - 100240
ER  -